ArticleJournal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology2021
Diagnostic and prognostic value of Technetium-99m pyrophosphate uptake quantitation for transthyretin cardiac amyloidosis.
Article in Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 47 citations in OpenAlex.
- Artificial intelligence-driven longitudinal quantification of technetium pyrophosphate uptake in cardiac amyloidosis: Correlation with multimodality imaging and outcomes.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2026Article
- Advances in imaging-based diagnosis, prognosis, and response assessment in cardiac amyloidosis: a comprehensive multimodality review.Annals of nuclear medicine · 2025Review
- A quantitative SPECT/CT metric for diagnosing transthyretin cardiac amyloidosis: multicenter study on biopsy-confirmed cases.European journal of nuclear medicine and molecular imaging · 2025Article
- Prognostic implication of DPD quantification in transthyretin cardiac amyloidosis.European heart journal. Cardiovascular Imaging · 2025Article
- The Accuracy of Technetium-99 m Pyrophosphate Imaging in Diagnosing Transthyretin Cardiac Amyloidosis and Its Impact on Patient Management.Current cardiology reports · 2025Review
- Deep Learning-Enabled Quantification ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024Article
- Transthyretin amyloid cardiomyopathy disease burden quantified usingJournal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2023Article
- Diagnostic value of heart-to-mediastinum ratio inJournal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2023Article
- Quantitative PYP metrics: separating the wheat from the chaff.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2023Article
- Echocardiographic indices of left ventricular function and filling pressure are not related to blood pool activity on pyrophosphate scintigraphy.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2023Article
- Does [99mTc]-3,3-diphosphono-1,2-propanodicarboxylic acid (DPD) soft tissue uptake allow the identification of patients with the diagnosis of cardiac transthyretin-related (ATTR) amyloidosis with higher risk for polyneuropathy?Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2023Article
- Review
- Correlation Between Cardiac Images, Biomarkers, and Amyloid Load in Wild-Type Transthyretin Amyloid Cardiomyopathy.Journal of the American Heart Association · 2022Article
- Review
- Pitfalls of the Semi-Quantitative AnalyzingDiagnostics (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
Abstract
backgroundMETHODS AND
resultsPatients who underwent
conclusionQuantitative assessment of myocardial radiotracer activity with CPA or VOI have high diagnostic accuracy for ATTR-CM. Both measures are potential non-invasive markers to follow progression of disease or response to therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.